DS
ODT

David Shaw’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

David Shaw’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-374,195
Closed -$505K – 6234
2021
Q4 		$505K Buy
374,195
+140,855
+60% +$333K ﹤0.01% 4400
2021
Q3 		$679K Sell
233,340
-106,728
-31% -$355K ﹤0.01% 3887
2021
Q2 		$1.19M Buy
340,068
+39,236
+13% +$135K ﹤0.01% 3401
2021
Q1 		$1.03M Buy
300,832
+149,732
+99% +$2.83M ﹤0.01% 3086
2020
Q4 		$2.9M Buy
151,100
+48,647
+47% +$751K ﹤0.01% 2302
2020
Q3 		$1.38M Buy
102,453
+1,378
+1% +$39K ﹤0.01% 2648
2020
Q2 		$4.28M Buy
101,075
+368
+0.4% +$11.9K 0.01% 1766
2020
Q1 		$2.78M Sell
100,707
-11,290
-10% -$329K ﹤0.01% 1908
2019
Q4 		$3.63M Buy
111,997
+41,913
+60% +$1.3M ﹤0.01% 1996
2019
Q3 		$1.82M Buy
+70,084
New +$2.35M ﹤0.01% 2424
2018
Q4 		– Sell
-18,359
Closed -$356K – 4091
2018
Q3 		$356K Sell
18,359
-2,423
-12% -$49.4K ﹤0.01% 3292
2018
Q2 		$459K Sell
20,782
-15,409
-43% -$359K ﹤0.01% 3169
2018
Q1 		$767K Buy
+36,191
New +$854K ﹤0.01% 2667

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

David Shaw's ODT Position: Q1 2022 in Review

David Shaw sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 374,195 shares — an estimated $505K sold.

David Shaw first reported a position in ODT in Q1 2018 and held it in 13 quarters. The position peaked at $4.28M in Q2 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • David Shaw reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • David Shaw sold 374,195 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $505K.
  • David Shaw first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2018 and held it in 13 quarters.
  • David Shaw's Odonate Therapeutics, Inc. Common Stock position peaked at $4.28M in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.